Global Haemophilus Parasuis Bivalent Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Global Haemophilus Parasuis Bivalent Vaccine Market Size, Share and Analysis

The global Haemophilus Parasuis Bivalent Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Haemophilus parasuis disease, also known as Grazers disease, is an upper respiratory infectious disease of pigs caused by Haemophilus parasuis (HPS), mainly infecting piglets before and after weaning, clinically manifested as multiple fibrosis Serositis, arthritis and meningitis. The inactivated vaccine against Haemophilus parasuis can effectively prevent Haemophilus parasuis and reduce the mortality rate of Haemophilus parasuis infection. United States market for Haemophilus Parasuis Bivalent Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. China market for Haemophilus Parasuis Bivalent Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Europe market for Haemophilus Parasuis Bivalent Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Global key Haemophilus Parasuis Bivalent Vaccine players cover Zoetis, Boehringer-Ingelheim, Eurovet, Hipra, Nisseiken, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024. Infinity Market Research newest research report, the Haemophilus Parasuis Bivalent Vaccine Industry Forecast looks at past sales and reviews total world Haemophilus Parasuis Bivalent Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Haemophilus Parasuis Bivalent Vaccine sales for 2025 through 2031. With Haemophilus Parasuis Bivalent Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Haemophilus Parasuis Bivalent Vaccine industry. This Insight Report provides a comprehensive analysis of the global Haemophilus Parasuis Bivalent Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Haemophilus Parasuis Bivalent Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Haemophilus Parasuis Bivalent Vaccine market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Haemophilus Parasuis Bivalent Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Haemophilus Parasuis Bivalent Vaccine. This report presents a comprehensive overview, market shares, and growth opportunities of Haemophilus Parasuis Bivalent Vaccine market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Bivalent Inactivated Vaccine &nbsp;&nbsp;&nbsp; Trivalent Inactivated Vaccine &nbsp;&nbsp;&nbsp; Quadrivalent Inactivated Vaccine Segmentation by Application: &nbsp;&nbsp;&nbsp; Piglets &nbsp;&nbsp;&nbsp; Adults Pigs This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Zoetis &nbsp;&nbsp;&nbsp; Boehringer-Ingelheim &nbsp;&nbsp;&nbsp; Eurovet &nbsp;&nbsp;&nbsp; Hipra &nbsp;&nbsp;&nbsp; Nisseiken &nbsp;&nbsp;&nbsp; Merck Animal Health &nbsp;&nbsp;&nbsp; SPAH &nbsp;&nbsp;&nbsp; Pulike Biological Engineering &nbsp;&nbsp;&nbsp; China Animal Husbandry Industry &nbsp;&nbsp;&nbsp; Wuhan Keqian Biology &nbsp;&nbsp;&nbsp; Wo Hua Biotech &nbsp;&nbsp;&nbsp; Zhejiang Ceva Ebvac Biotech &nbsp;&nbsp;&nbsp; Luoyang Huizhong Biotech &nbsp;&nbsp;&nbsp; Beijing Centrebio Biology &nbsp;&nbsp;&nbsp; Shandong Huahong Bioengineering &nbsp;&nbsp;&nbsp; Ringpu Key Questions Addressed in this Report What is the 10-year outlook for the global Haemophilus Parasuis Bivalent Vaccine market? What factors are driving Haemophilus Parasuis Bivalent Vaccine market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Haemophilus Parasuis Bivalent Vaccine market opportunities vary by end market size? How does Haemophilus Parasuis Bivalent Vaccine break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Haemophilus Parasuis Bivalent Vaccine Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Haemophilus Parasuis Bivalent Vaccine by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Haemophilus Parasuis Bivalent Vaccine by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Haemophilus Parasuis Bivalent Vaccine Segment by Type &nbsp;2.2.1 Bivalent Inactivated Vaccine &nbsp;2.2.2 Trivalent Inactivated Vaccine &nbsp;2.2.3 Quadrivalent Inactivated Vaccine &nbsp;2.3 Haemophilus Parasuis Bivalent Vaccine Sales by Type &nbsp;2.3.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Haemophilus Parasuis Bivalent Vaccine Sale Price by Type (2020-2025) &nbsp;2.4 Haemophilus Parasuis Bivalent Vaccine Segment by Application &nbsp;2.4.1 Piglets &nbsp;2.4.2 Adults Pigs &nbsp;2.5 Haemophilus Parasuis Bivalent Vaccine Sales by Application &nbsp;2.5.1 Global Haemophilus Parasuis Bivalent Vaccine Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Haemophilus Parasuis Bivalent Vaccine Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Haemophilus Parasuis Bivalent Vaccine Breakdown Data by Company &nbsp;3.1.1 Global Haemophilus Parasuis Bivalent Vaccine Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Haemophilus Parasuis Bivalent Vaccine Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Company (2020-2025) &nbsp;3.2.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Haemophilus Parasuis Bivalent Vaccine Sale Price by Company &nbsp;3.4 Key Manufacturers Haemophilus Parasuis Bivalent Vaccine Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Haemophilus Parasuis Bivalent Vaccine Product Location Distribution &nbsp;3.4.2 Players Haemophilus Parasuis Bivalent Vaccine Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Haemophilus Parasuis Bivalent Vaccine by Geographic Region &nbsp;4.1 World Historic Haemophilus Parasuis Bivalent Vaccine Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Haemophilus Parasuis Bivalent Vaccine Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Haemophilus Parasuis Bivalent Vaccine Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Haemophilus Parasuis Bivalent Vaccine Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Haemophilus Parasuis Bivalent Vaccine Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Haemophilus Parasuis Bivalent Vaccine Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Haemophilus Parasuis Bivalent Vaccine Sales Growth &nbsp;4.4 APAC Haemophilus Parasuis Bivalent Vaccine Sales Growth &nbsp;4.5 Europe Haemophilus Parasuis Bivalent Vaccine Sales Growth &nbsp;4.6 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Growth 5 Americas &nbsp;5.1 Americas Haemophilus Parasuis Bivalent Vaccine Sales by Country &nbsp;5.1.1 Americas Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2025) &nbsp;5.1.2 Americas Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2025) &nbsp;5.2 Americas Haemophilus Parasuis Bivalent Vaccine Sales by Type (2020-2025) &nbsp;5.3 Americas Haemophilus Parasuis Bivalent Vaccine Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Haemophilus Parasuis Bivalent Vaccine Sales by Region &nbsp;6.1.1 APAC Haemophilus Parasuis Bivalent Vaccine Sales by Region (2020-2025) &nbsp;6.1.2 APAC Haemophilus Parasuis Bivalent Vaccine Revenue by Region (2020-2025) &nbsp;6.2 APAC Haemophilus Parasuis Bivalent Vaccine Sales by Type (2020-2025) &nbsp;6.3 APAC Haemophilus Parasuis Bivalent Vaccine Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Haemophilus Parasuis Bivalent Vaccine by Country &nbsp;7.1.1 Europe Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2025) &nbsp;7.1.2 Europe Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2025) &nbsp;7.2 Europe Haemophilus Parasuis Bivalent Vaccine Sales by Type (2020-2025) &nbsp;7.3 Europe Haemophilus Parasuis Bivalent Vaccine Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine by Country &nbsp;8.1.1 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Haemophilus Parasuis Bivalent Vaccine &nbsp;10.3 Manufacturing Process Analysis of Haemophilus Parasuis Bivalent Vaccine &nbsp;10.4 Industry Chain Structure of Haemophilus Parasuis Bivalent Vaccine 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Haemophilus Parasuis Bivalent Vaccine Distributors &nbsp;11.3 Haemophilus Parasuis Bivalent Vaccine Customer 12 World Forecast Review for Haemophilus Parasuis Bivalent Vaccine by Geographic Region &nbsp;12.1 Global Haemophilus Parasuis Bivalent Vaccine Market Size Forecast by Region &nbsp;12.1.1 Global Haemophilus Parasuis Bivalent Vaccine Forecast by Region (2026-2031) &nbsp;12.1.2 Global Haemophilus Parasuis Bivalent Vaccine Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Haemophilus Parasuis Bivalent Vaccine Forecast by Type (2026-2031) &nbsp;12.7 Global Haemophilus Parasuis Bivalent Vaccine Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Zoetis &nbsp;13.1.1 Zoetis Company Information &nbsp;13.1.2 Zoetis Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.1.3 Zoetis Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Zoetis Main Business Overview &nbsp;13.1.5 Zoetis Latest Developments &nbsp;13.2 Boehringer-Ingelheim &nbsp;13.2.1 Boehringer-Ingelheim Company Information &nbsp;13.2.2 Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.2.3 Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Boehringer-Ingelheim Main Business Overview &nbsp;13.2.5 Boehringer-Ingelheim Latest Developments &nbsp;13.3 Eurovet &nbsp;13.3.1 Eurovet Company Information &nbsp;13.3.2 Eurovet Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.3.3 Eurovet Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Eurovet Main Business Overview &nbsp;13.3.5 Eurovet Latest Developments &nbsp;13.4 Hipra &nbsp;13.4.1 Hipra Company Information &nbsp;13.4.2 Hipra Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.4.3 Hipra Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Hipra Main Business Overview &nbsp;13.4.5 Hipra Latest Developments &nbsp;13.5 Nisseiken &nbsp;13.5.1 Nisseiken Company Information &nbsp;13.5.2 Nisseiken Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.5.3 Nisseiken Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Nisseiken Main Business Overview &nbsp;13.5.5 Nisseiken Latest Developments &nbsp;13.6 Merck Animal Health &nbsp;13.6.1 Merck Animal Health Company Information &nbsp;13.6.2 Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.6.3 Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Merck Animal Health Main Business Overview &nbsp;13.6.5 Merck Animal Health Latest Developments &nbsp;13.7 SPAH &nbsp;13.7.1 SPAH Company Information &nbsp;13.7.2 SPAH Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.7.3 SPAH Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 SPAH Main Business Overview &nbsp;13.7.5 SPAH Latest Developments &nbsp;13.8 Pulike Biological Engineering &nbsp;13.8.1 Pulike Biological Engineering Company Information &nbsp;13.8.2 Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.8.3 Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Pulike Biological Engineering Main Business Overview &nbsp;13.8.5 Pulike Biological Engineering Latest Developments &nbsp;13.9 China Animal Husbandry Industry &nbsp;13.9.1 China Animal Husbandry Industry Company Information &nbsp;13.9.2 China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.9.3 China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 China Animal Husbandry Industry Main Business Overview &nbsp;13.9.5 China Animal Husbandry Industry Latest Developments &nbsp;13.10 Wuhan Keqian Biology &nbsp;13.10.1 Wuhan Keqian Biology Company Information &nbsp;13.10.2 Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.10.3 Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Wuhan Keqian Biology Main Business Overview &nbsp;13.10.5 Wuhan Keqian Biology Latest Developments &nbsp;13.11 Wo Hua Biotech &nbsp;13.11.1 Wo Hua Biotech Company Information &nbsp;13.11.2 Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.11.3 Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Wo Hua Biotech Main Business Overview &nbsp;13.11.5 Wo Hua Biotech Latest Developments &nbsp;13.12 Zhejiang Ceva Ebvac Biotech &nbsp;13.12.1 Zhejiang Ceva Ebvac Biotech Company Information &nbsp;13.12.2 Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.12.3 Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Zhejiang Ceva Ebvac Biotech Main Business Overview &nbsp;13.12.5 Zhejiang Ceva Ebvac Biotech Latest Developments &nbsp;13.13 Luoyang Huizhong Biotech &nbsp;13.13.1 Luoyang Huizhong Biotech Company Information &nbsp;13.13.2 Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.13.3 Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Luoyang Huizhong Biotech Main Business Overview &nbsp;13.13.5 Luoyang Huizhong Biotech Latest Developments &nbsp;13.14 Beijing Centrebio Biology &nbsp;13.14.1 Beijing Centrebio Biology Company Information &nbsp;13.14.2 Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.14.3 Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Beijing Centrebio Biology Main Business Overview &nbsp;13.14.5 Beijing Centrebio Biology Latest Developments &nbsp;13.15 Shandong Huahong Bioengineering &nbsp;13.15.1 Shandong Huahong Bioengineering Company Information &nbsp;13.15.2 Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.15.3 Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 Shandong Huahong Bioengineering Main Business Overview &nbsp;13.15.5 Shandong Huahong Bioengineering Latest Developments &nbsp;13.16 Ringpu &nbsp;13.16.1 Ringpu Company Information &nbsp;13.16.2 Ringpu Haemophilus Parasuis Bivalent Vaccine Product Portfolios and Specifications &nbsp;13.16.3 Ringpu Haemophilus Parasuis Bivalent Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.16.4 Ringpu Main Business Overview &nbsp;13.16.5 Ringpu Latest Developments 14 Research Findings and Conclusion

Report	Global Haemophilus Parasuis Bivalent Vaccine Market Growth, Trends and Opportunities 2025-31
Selected License	Multi ID: LPI50389

Buyer Information

Order Summary